Drug firms eye fat profits from new obesity pills (Reuters)


<p><a href="http://us.rd.yahoo.com/dailynews/rss/health/*http://news.yahoo.com/s/nm/20060116/hl_nm/obesity_dc"><img src="http://us.news3.yimg.com/us.i2.yimg.com/p/rids/20060116/i/r529193369.jpg?x=130&y=81&sig=JbR7vy7.qROFb6RLPB67fw--" align="left" height="81" width="130" alt="An unidentified man smokes a cannabis cigarette at a house in London in this January 24, 2004 file photo. A compound switching off the same brain circuits that make people hungry when they smoke cannabis looks set to become the world's first blockbuster anti-obesity medicine, with sales tipped by analysts to top $3 billion a year. Sanofi-Aventis SA's Acomplia, or rimonabant, which could be approved by U.S. regulators as early as next month, is the first of a new wave of treatments that may spell fat profits for some pharmaceutical companies. To match feature Health-Obesity. To match feature Health-Obesity. REUTERS/David Bebber/Files" border="0" /></a>Reuters - A marijuana joint might seem an odd
starting point in the search for weight-loss secrets.</p><br clear=all>